Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study

被引：1

作者：

Gavriatopoulou, Maria ^{[1
]}

Vogl, Dan T. ^{[2
]}

Nooka, Ajay ^{[3
]}

Dingli, David ^{[4
]}

Cole, Craig ^{[5
]}

Moreau, Philippe ^{[6
]}

Huff, Carol ^{[7
]}

Yee, Andrew ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

Lonial, Sagar ^{[10
]}

Richardson, Paul G. ^{[11
]}

Stewart, Keith ^{[12
]}

Chari, Ajai ^{[13
]}

Richter, Joshua ^{[14
]}

Biran, Noa ^{[14
]}

Siegel, David S. ^{[15
]}

Liu, Jianjun ^{[16
]}

Joshi, Anita ^{[16
]}

Shah, Jatin ^{[16
]}

Shacham, Sharon ^{[16
]}

Kauffman, Michael ^{[16
]}

Jagannath, Sundar ^{[17
]}

机构：

[1] Univ Athens, Sch Med, Athens, Greece

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] Mayo Clin, Rochester, MN USA

[5] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[6] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France

[7] Johns Hopkins Univ, Baltimore, MD USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[9] Univ Athens, Sch Med, Alexandra Hosp, Athens, Greece

[10] Emory Univ, Atlanta, GA 30322 USA

[11] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[12] Mayo Clin, Scottsdale, AZ USA

[13] Mt Sinai Sch Med, New York, NY USA

[14] Hackensack Univ, John Theurer Canc Ctr, Hackensack, NJ USA

[15] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[16] Karyopharm Therapeut Inc, Newton, MA USA

[17] Mt Sinai Hosp, New York, NY 10029 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Elderly patients; novel agents; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.195

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FP-110

引用

页码：E117 / E118

页数：2

共 50 条

[31] Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
Gueneau, Pauline
Chretien, Marie-Lorraine
Cransac-Miet, Amelie
Aho, Ludwig Serge
Lafon, Ingrid
Favennec, Camille
Guy, Julien
Caillot, Denis
Boulin, Mathieu
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 518 - 525
[32] Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
Lonial, Sagar
Nooka, Ajay
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie
Callander, Natalie S.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Baron, January
Doherty, Allison
Lewis, Eric
Opalinska, Joanna
Paka, Prani
Piontek, Trisha
Gupta, Ira
Farooq, Asim V.
Jakubowiak, Andrzej
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S149 - S150
[33] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma
Chen, Pingping
Ma, Jiexian
Qian, Wensi
Wu, Min
Shen, Lin
Xie, Yanhui
MINERVA PEDIATRICS, 2024, 76 (01): : 121 - 123
[34] A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma
Noopur, Raje
Xavier, Leleu
Alexander, Lesokhin M.
Mohamed, Mohty
Ajay, Nooka
Eric, Leip
Umberto, Conte
Andrea, Vlqueira
Saloman, Manier
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S17 - S18
[35] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary E.
Feng, Huaibao
Brun, Nikolai Constantin
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
BLOOD, 2014, 124 (21)
[36] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 104 - 104
[37] SYMPTOM MANAGEMENT FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING THERAPY WITH SELINEXOR (XPOVIO™)
Florendo, Erika
Mancia, Ines Stefania
Thomas, Joanne
ONCOLOGY NURSING FORUM, 2020, 47 (02)
[38] Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
Botta, Cirino
Ciliberto, Domenico
Rossi, Marco
Staropoli, Nicoletta
Cuce, Maria
Galeano, Teresa
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
BLOOD ADVANCES, 2017, 1 (07) : 455 - 466
[39] Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
Gordan, Lucio N.
Ray, David
Ijioma, Stephen C.
Dranitsaris, George
Warner, Amanda
Heritage, Trevor
Fink, Matthew
Wenk, David
Chadwick, Paul
Khrystolubova, Natasha
Peles, Shachar
CURRENT ONCOLOGY, 2024, 31 (01) : 501 - 510
[40] Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Florendo, Erika
Mancia, Ines Stefania
Cho, Hearn
Madduri, Deepu
Parekh, Samir
Richter, Josh
Dhadwal, Amishi
Thomas, Joanne
Jiang, Grace
Lagana, Alessandro
Bhalla, Sherry
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : E975 - E984

← 1 2 3 4 5 →